Search research articles
Contact Us
Filters
Showing results (51-60 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
ESMO Open
|
April 30, 2021
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
L Paz-Ares, F Barlesi, S Siena, et al.
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
F Pommeret, J Colomba, C Bigenwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2021
Severe COVID-19 in patients with hematological cancers presenting with viremia
J M Michot, T Hueso, N Ibrahimi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
J Vansteenkiste, F Barlesi, C F Waller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F Barlesi, A Scherpereel, V Gorbunova, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
ESMO Open
|
April 30, 2021
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
L Paz-Ares, F Barlesi, S Siena, et al.
Revue Des Maladies Respiratoires
|
February 22, 2008
[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]
D Moro-Sibilot, F Barlesi, J F Timsit, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
F Pommeret, J Colomba, C Bigenwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2014
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer
S Novello, B Besse, E Felip, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 15, 2021
Severe COVID-19 in patients with hematological cancers presenting with viremia
J M Michot, T Hueso, N Ibrahimi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 15, 2014
Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer
G V Scagliotti, I Bondarenko, F Blackhall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 6, 2015
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
J Vansteenkiste, F Barlesi, C F Waller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
J Mazières, F Barlesi, T Filleron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2014
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F Barlesi, A Scherpereel, V Gorbunova, et al.
Page
of 9